|02/15/18||AbbVie Increases Dividend and Announces New Stock Repurchase Program|
|NORTH CHICAGO, Ill., Feb. 15, 2018 /PRNewswire/ -- The board of directors of AbbVie (NYSE: ABBV) increased the company's quarterly cash dividend by 35 percent from $0.71 per share to $0.96 per share and authorized a new $10 billion stock repurchase program.
The cash dividend is payable May 15, 2018 to stockholders of record at the close of business on April 13, 2018.
Since the company's inception in 2013, AbbVie has increased its dividend by 140 percent. AbbVie is a member of the S&P Div... |
|01/26/18||AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results|
|- Reports Full-Year Diluted EPS of $3.30 on a GAAP Basis; Adjusted Diluted EPS of $5.60 Reflects Growth of 16.2 Percent
- Delivers Full-Year Net Revenues of $28.216 Billion; Adjusted Net Revenues Increased 10.1 Percent on an Operational Basis
- Full-Year Global HUMIRA Sales of $18.427 Billion Increased 14.6 Percent on a Reported Basis, or 14.4 Percent on an Operational Basis
- Full-Year Global IMBRUVICA Net Revenues Were $2.573 Billion, an Increase of 40.5 Percent
- Reports Fourth-Qu... |
|01/12/18||AbbVie to Host Fourth-Quarter 2017 Earnings Conference Call|
|NORTH CHICAGO, Ill., Jan. 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter 2017 financial results on Friday, Jan. 26, 2018, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.
AbbVie is a global, research-driven biophar... |